Cargando…

Cost-Effectiveness Analysis of Screening for and Managing Identified Hypertension for Cardiovascular Disease Prevention in Vietnam

OBJECTIVE: To inform development of guidelines for hypertension management in Vietnam, we evaluated the cost-effectiveness of different strategies on screening for hypertension in preventing cardiovascular disease (CVD). METHODS: A decision tree was combined with a Markov model to measure incrementa...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Thi-Phuong-Lan, Wright, E. Pamela, Nguyen, Thanh-Trung, Schuiling-Veninga, C. C. M., Bijlsma, M. J., Nguyen, Thi-Bach-Yen, Postma, M. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4871542/
https://www.ncbi.nlm.nih.gov/pubmed/27192051
http://dx.doi.org/10.1371/journal.pone.0155699
_version_ 1782432614772113408
author Nguyen, Thi-Phuong-Lan
Wright, E. Pamela
Nguyen, Thanh-Trung
Schuiling-Veninga, C. C. M.
Bijlsma, M. J.
Nguyen, Thi-Bach-Yen
Postma, M. J.
author_facet Nguyen, Thi-Phuong-Lan
Wright, E. Pamela
Nguyen, Thanh-Trung
Schuiling-Veninga, C. C. M.
Bijlsma, M. J.
Nguyen, Thi-Bach-Yen
Postma, M. J.
author_sort Nguyen, Thi-Phuong-Lan
collection PubMed
description OBJECTIVE: To inform development of guidelines for hypertension management in Vietnam, we evaluated the cost-effectiveness of different strategies on screening for hypertension in preventing cardiovascular disease (CVD). METHODS: A decision tree was combined with a Markov model to measure incremental cost-effectiveness of different approaches to hypertension screening. Values used as input parameters for the model were taken from different sources. Various screening intervals (one-off, annually, biannually) and starting ages to screen (35, 45 or 55 years) and coverage of treatment were analysed. We ran both a ten-year and a lifetime horizon. Input parameters for the models were extracted from local and regional data. Probabilistic sensitivity analysis was used to evaluate parameter uncertainty. A threshold of three times GDP per capita was applied. RESULTS: Cost per quality adjusted life year (QALY) gained varied in different screening scenarios. In a ten-year horizon, the cost-effectiveness of screening for hypertension ranged from cost saving to Int$ 758,695 per QALY gained. For screening of men starting at 55 years, all screening scenarios gave a high probability of being cost-effective. For screening of females starting at 55 years, the probability of favourable cost-effectiveness was 90% with one-off screening. In a lifetime horizon, cost per QALY gained was lower than the threshold of Int$ 15,883 in all screening scenarios among males. Similar results were found in females when starting screening at 55 years. Starting screening in females at 45 years had a high probability of being cost-effective if screening biannually was combined with increasing coverage of treatment by 20% or even if sole biannual screening was considered. CONCLUSION: From a health economic perspective, integrating screening for hypertension into routine medical examination and related coverage by health insurance could be recommended. Screening for hypertension has a high probability of being cost-effective in preventing CVD. An adequate screening strategy can best be selected based on age, sex and screening interval.
format Online
Article
Text
id pubmed-4871542
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-48715422016-05-31 Cost-Effectiveness Analysis of Screening for and Managing Identified Hypertension for Cardiovascular Disease Prevention in Vietnam Nguyen, Thi-Phuong-Lan Wright, E. Pamela Nguyen, Thanh-Trung Schuiling-Veninga, C. C. M. Bijlsma, M. J. Nguyen, Thi-Bach-Yen Postma, M. J. PLoS One Research Article OBJECTIVE: To inform development of guidelines for hypertension management in Vietnam, we evaluated the cost-effectiveness of different strategies on screening for hypertension in preventing cardiovascular disease (CVD). METHODS: A decision tree was combined with a Markov model to measure incremental cost-effectiveness of different approaches to hypertension screening. Values used as input parameters for the model were taken from different sources. Various screening intervals (one-off, annually, biannually) and starting ages to screen (35, 45 or 55 years) and coverage of treatment were analysed. We ran both a ten-year and a lifetime horizon. Input parameters for the models were extracted from local and regional data. Probabilistic sensitivity analysis was used to evaluate parameter uncertainty. A threshold of three times GDP per capita was applied. RESULTS: Cost per quality adjusted life year (QALY) gained varied in different screening scenarios. In a ten-year horizon, the cost-effectiveness of screening for hypertension ranged from cost saving to Int$ 758,695 per QALY gained. For screening of men starting at 55 years, all screening scenarios gave a high probability of being cost-effective. For screening of females starting at 55 years, the probability of favourable cost-effectiveness was 90% with one-off screening. In a lifetime horizon, cost per QALY gained was lower than the threshold of Int$ 15,883 in all screening scenarios among males. Similar results were found in females when starting screening at 55 years. Starting screening in females at 45 years had a high probability of being cost-effective if screening biannually was combined with increasing coverage of treatment by 20% or even if sole biannual screening was considered. CONCLUSION: From a health economic perspective, integrating screening for hypertension into routine medical examination and related coverage by health insurance could be recommended. Screening for hypertension has a high probability of being cost-effective in preventing CVD. An adequate screening strategy can best be selected based on age, sex and screening interval. Public Library of Science 2016-05-18 /pmc/articles/PMC4871542/ /pubmed/27192051 http://dx.doi.org/10.1371/journal.pone.0155699 Text en © 2016 Nguyen et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Nguyen, Thi-Phuong-Lan
Wright, E. Pamela
Nguyen, Thanh-Trung
Schuiling-Veninga, C. C. M.
Bijlsma, M. J.
Nguyen, Thi-Bach-Yen
Postma, M. J.
Cost-Effectiveness Analysis of Screening for and Managing Identified Hypertension for Cardiovascular Disease Prevention in Vietnam
title Cost-Effectiveness Analysis of Screening for and Managing Identified Hypertension for Cardiovascular Disease Prevention in Vietnam
title_full Cost-Effectiveness Analysis of Screening for and Managing Identified Hypertension for Cardiovascular Disease Prevention in Vietnam
title_fullStr Cost-Effectiveness Analysis of Screening for and Managing Identified Hypertension for Cardiovascular Disease Prevention in Vietnam
title_full_unstemmed Cost-Effectiveness Analysis of Screening for and Managing Identified Hypertension for Cardiovascular Disease Prevention in Vietnam
title_short Cost-Effectiveness Analysis of Screening for and Managing Identified Hypertension for Cardiovascular Disease Prevention in Vietnam
title_sort cost-effectiveness analysis of screening for and managing identified hypertension for cardiovascular disease prevention in vietnam
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4871542/
https://www.ncbi.nlm.nih.gov/pubmed/27192051
http://dx.doi.org/10.1371/journal.pone.0155699
work_keys_str_mv AT nguyenthiphuonglan costeffectivenessanalysisofscreeningforandmanagingidentifiedhypertensionforcardiovasculardiseasepreventioninvietnam
AT wrightepamela costeffectivenessanalysisofscreeningforandmanagingidentifiedhypertensionforcardiovasculardiseasepreventioninvietnam
AT nguyenthanhtrung costeffectivenessanalysisofscreeningforandmanagingidentifiedhypertensionforcardiovasculardiseasepreventioninvietnam
AT schuilingveningaccm costeffectivenessanalysisofscreeningforandmanagingidentifiedhypertensionforcardiovasculardiseasepreventioninvietnam
AT bijlsmamj costeffectivenessanalysisofscreeningforandmanagingidentifiedhypertensionforcardiovasculardiseasepreventioninvietnam
AT nguyenthibachyen costeffectivenessanalysisofscreeningforandmanagingidentifiedhypertensionforcardiovasculardiseasepreventioninvietnam
AT postmamj costeffectivenessanalysisofscreeningforandmanagingidentifiedhypertensionforcardiovasculardiseasepreventioninvietnam